Showing 3331-3340 of 6665 results for "".
- Rejuva Fresh Launches Upgraded Custom CORE™ 8D Multi-Platform Laserhttps://practicaldermatology.com/news/rejuva-fresh-launches-upgraded-custom-coretm-8d-multi-platform-laser/2475979/Rejuva Fresh has announced the release of its updated Custom CORE™ 8D Multi-Platform Laser, according to a press release from the manufacturer.
- FDA Speeds Development of Hair Loss Drug Rezpegaldesleukinhttps://practicaldermatology.com/news/fda-speeds-development-of-nektars-autoimmune-hair-loss-drug/2475953/The FDA has granted Fast Track designation to the investigational biologic rezpegaldesleukin (Nektar Therapeutics) for the treatment of severe-to-very severe alopecia areata (AA) in adults and adolescents aged 12 and older who weigh at least 40 kg.
- NPF and Boehringer Unite to Launch First GPP Awareness Dayhttps://practicaldermatology.com/news/NPF-Boehringer-Unite-Launch-First-GPP-Awareness-Day/2475890/Key Takeaways NPF and Boehringer Ingelheim launched a campaign to educate and support individuals with generalized pustular psoriasis.
- Multimodal "Toolkit" Enhances AI Detection of Skin Lesions: Researchershttps://practicaldermatology.com/news/multimodal-dataset-enhances-ai-detection-of-skin-lesions/2475786/A new open-access dataset, MILK10k, provides over 10,000 multimodal images to improve machine learning performance in the diagnosis of both pigmented and non-pigmented skin cancers and simulators. According to researchers publ
- ADmirable Trial: Lebrikizumab Shows Efficacy in AD Among Skin of Color Populationshttps://practicaldermatology.com/news/admirable-lebrikizumab-shows-efficacy-in-ad-among-skin-of-color-populations/2475811/Lebrikizumab significantly improved atopic dermatitis (AD) outcomes in patients with skin of color in the ADmirable phase 3b trial. The ADmirable study, and open-label, 24-week trial evaluating lebrikizumab in patients with F
- Long-Term Ixekizumab Use Not Linked to Increased Cancer Risk: Analysishttps://practicaldermatology.com/news/long-term-ixekizumab-use-not-linked-to-increased-cancer-risk/2475704/Long-term treatment with ixekizumab (IXE) for psoriasis, psoriatic arthritis, and axial spondyloarthritis was not associated with increased risk of malignant neoplasms, according to a new analysis of pooled data from 25 randomized clinical trials.
- LEQSELVI™ Launches in U.S. as Oral Treatment for Severe Alopecia Areatahttps://practicaldermatology.com/news/leqselvitm-launches-in-us-as-oral-treatment-for-severe-alopecia-areata/2475680/Sun Pharmaceutical Industries Ltd. announced the U.S. commercial availability of LEQSELVI™ (deuruxolitinib), an oral Janus kinase (JAK) inhibitor indicated for the treatment of adults with severe alopecia areata, according to a press release from the manufacturer.
- LEO Pharma to Partner with Boehringer Ingelheim, Commercialize SPEVIGO® for GPPhttps://practicaldermatology.com/news/leo-pharma-to-partner-with-boehringer-ingelheim-commercialize-spevigo-for-gpp/2475663/LEO Pharma and Boehringer Ingelheim have entered into an exclusive global license and transfer agreement for the development and commercialization of the interleukin-36 (IL-36) receptor inhibitor SPEVIGO® (spesolimab), according to a news release.
- Anaysis: Linperlisib and Chidamide Safe, Effective in Advanced CTCLhttps://practicaldermatology.com/news/anaysis-linperlisib-and-chidamide-safe-effective-in-advanced-ctcl/2475518/An investigational combination of linperlisib and chidamide demonstrated clinical activity in patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL), according to results from a phase 1 trial. The single-arm, n
- Study: 90% Would Purchase Red Light Therapy Deviceshttps://practicaldermatology.com/news/study-90-would-purchase-red-light-therapy-devices/2475498/New research published in the Journal of Clinical and Aesthetic Dermatology showed how social media is fueling the growing consumer demand for over-the-counter (OTC) red light therapy (RLT) devices. The authors of the